274 related articles for article (PubMed ID: 29471699)
1. Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential.
Tapia Rico G; Price TJ
Expert Opin Biol Ther; 2018 Apr; 18(4):449-457. PubMed ID: 29471699
[TBL] [Abstract][Full Text] [Related]
2. Prospects and progress of atezolizumab in non-small cell lung cancer.
Vansteenkiste J; Wauters E; Park K; Rittmeyer A; Sandler A; Spira A
Expert Opin Biol Ther; 2017 Jun; 17(6):781-789. PubMed ID: 28335643
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for colorectal cancer: where are we heading?
Basile D; Garattini SK; Bonotto M; Ongaro E; Casagrande M; Cattaneo M; Fanotto V; De Carlo E; Loupakis F; Urbano F; Negri FV; Pella N; Russano M; Brunetti O; Scartozzi M; Santini D; Silvestris N; Casadei Gardini A; Puzzoni M; Calvetti L; Cardarelli N; Aprile G
Expert Opin Biol Ther; 2017 Jun; 17(6):709-721. PubMed ID: 28375039
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
Morse MA; Hochster H; Benson A
Oncologist; 2020 Jan; 25(1):33-45. PubMed ID: 31383813
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab in invasive and metastatic urothelial carcinoma.
Crist M; Balar A
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
[TBL] [Abstract][Full Text] [Related]
6. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research.
Wensink E; Bond M; Kucukkose E; May A; Vink G; Koopman M; Kranenburg O; Roodhart J
Cancer Treat Rev; 2021 Apr; 95():102174. PubMed ID: 33721596
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.
Krishnamurthy A; Jimeno A
Drugs Today (Barc); 2017 Apr; 53(4):217-237. PubMed ID: 28492290
[TBL] [Abstract][Full Text] [Related]
8. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
Emambux S; Tachon G; Junca A; Tougeron D
Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
Patel R; Bock M; Polotti CF; Elsamra S
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):225-232. PubMed ID: 28043166
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
11. Product review on the Anti-PD-L1 antibody atezolizumab.
Shah NJ; Kelly WJ; Liu SV; Choquette K; Spira A
Hum Vaccin Immunother; 2018 Feb; 14(2):269-276. PubMed ID: 29194007
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab for the treatment of triple-negative breast cancer.
Heimes AS; Schmidt M
Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425
[TBL] [Abstract][Full Text] [Related]
13. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
14. [Atezolizumab (Tecentriq
Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
Bull Cancer; 2018 Feb; 105(2):140-145. PubMed ID: 29290331
[TBL] [Abstract][Full Text] [Related]
15. [Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].
Chen G
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):28-33. PubMed ID: 28105616
[TBL] [Abstract][Full Text] [Related]
16. MEDI 4736 (durvalumab) in non-small cell lung cancer.
Jeanson A; Barlesi F
Expert Opin Biol Ther; 2017 Oct; 17(10):1317-1323. PubMed ID: 28705024
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab for treating non-small cell lung cancer.
Guibert N; Mazières J
Expert Opin Biol Ther; 2015; 15(12):1789-97. PubMed ID: 26574148
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.
Battaglin F; Dadduzio V; Bergamo F; Manai C; Schirripa M; Lonardi S; Zagonel V; Loupakis F
Expert Opin Biol Ther; 2017 Oct; 17(10):1297-1308. PubMed ID: 28752777
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab for the treatment of bladder cancer.
Hakenberg OW
Expert Opin Biol Ther; 2017 Oct; 17(10):1309-1315. PubMed ID: 28737430
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]